(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R, 6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses. (13th May 2019)

• Record Type: Journal Article
• Authors: Zanos, Panos; Highland, Jaclyn N.; Liu, Xin; Troppoli, Timothy A.; Georgiou, Polymnia; Lovett, Jacqueline; Morris, Patrick J.; Stewart, Brent W.; Thomas, Craig J.; Thompson, Scott M.; Moaddel, Ruin; Gould, Todd D.
• Is Part Of: British journal of pharmacology. Volume 176:Number 14(2019)
• Page Start: 2573
• Page End: 2592
• Publication Date: 2019-05-13
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.14683
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: ( R )‐Ketamine (arketamine) may have utility as a rapidly acting antidepressant. While ( R )‐ketamine has lower potency than ( R, S )‐ketamine to inhibit NMDA receptors in vitro, the extent to which ( R )‐ketamine shares the NMDA receptor‐mediated adverse effects of ( R, S )‐ketamine in vivo has not been fully characterised. Furthermore, ( R )‐ketamine is metabolised to ( 2R, 6R )‐hydroxynorketamine (HNK), which may contribute to its antidepressant‐relevant actions. Experimental Approach: Using mice, we compared ( R )‐ketamine with a deuterated form of the drug (6, 6‐dideutero‐( R )‐ketamine, ( R )‐d2 ‐ketamine), which hinders its metabolism to ( 2R, 6R )‐HNK, in behavioural tests predicting antidepressant responses. We also examined the actions of intracerebroventricularly infused ( 2R, 6R )‐HNK. Further, we quantified putative NMDA receptor inhibition‐mediated adverse effects of ( R )‐ketamine. Key Results: ( R )‐d2 ‐Ketamine was identical to ( R )‐ketamine in binding to and functionally inhibiting NMDA receptors but hindered ( R )‐ketamine's metabolism to ( 2R, 6R )‐HNK. ( R )‐Ketamine exerted greater potency than ( R )‐d2 ‐ketamine in several antidepressant‐sensitive behavioural measures, consistent with a role of ( 2R, 6R )‐HNK in the actions of ( R )‐ketamine. There were dose‐dependent sustained antidepressant‐relevant actions of ( 2R, 6R )‐HNK following intracerebroventricular administration. ( R )‐Ketamine exerted NMDA receptor inhibition‐mediated behaviours similar to ( R, S )‐ketamine, including locomotor stimulation, conditioned‐place preference, prepulse inhibition deficits, and motor incoordination, with approximately half the potency of the racemic drug. Conclusions and Implications: Metabolism of ( R )‐ketamine to ( 2R, 6R )‐HNK increases the potency of ( R )‐ketamine to exert antidepressant‐relevant actions in mice. Adverse effects of ( R )‐ketamine require higher doses than those necessary for antidepressant‐sensitive behavioural changes in mice. However, our data revealing that ( R )‐ketamine's adverse effects are elicited at sub‐anaesthetic doses indicate a potential risk for sensory dissociation and abuse liability.